AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
$17.01
-1.90%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders3 funds
Inst. Value$395.1K
Inst. Activity1 buys / 0 sells
SEC Reports11
Press Releases7
Recent Activity
Jun 15, 2026
SEC
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two core assets olveremb
6-K — Impact 6/10
Jun 14, 2026
fda
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage P
Jun 1, 2026
SEC
Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, including first pediatric
6-K — Impact 4/10
May 28, 2026
SEC
Ascentage Pharma disclosed that its trustee purchased 50,000 existing shares on-market for HK$1,909,800 (HK$38.196/share
6-K — Impact 2/10
May 21, 2026
Insider
Yang Dajun acquired via exercise 95,575 shares
Chairman and CEO
May 21, 2026
Insider
Zhai Yifan acquired via exercise 92,746 shares
Chief Medical Officer
May 20, 2026
Insider
Yang Dajun was granted 95,575 shares
Chairman and CEO
Inst.
MORGAN STANLEY — DOUBLED
498 shares ($11.9K)
Price Targets
$47.56
+179.6% upside
Strong Buy
Current $17.01
Low $40.00
Median $48.00
High $55.00
9 analysts
$40.00
$55.00
Analyst Ratings
5Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 15, 2026 | BTIG | REITERATE | Buy → Buy |
| Jun 10, 2026 | B. Riley Securities | INITIATE | Buy |
| Apr 13, 2026 | BTIG | REITERATE | Buy → Buy |
| Mar 26, 2026 | BTIG | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.58 | $-0.58 — $-0.58 | 1 | |
| Next Q | $-0.51 | $-0.51 — $-0.51 | 1 | |
| Current FY | $-1.52 | $-2.50 — $-0.43 | 24% YoY | 5 |
| Next FY | $-1.20 | $-2.28 — $-0.28 | 21% YoY | 4 |
Latest Reports
BULLISH
6-K
6/10
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two core assets olveremb
Jun 15, 2026
MIXED
Press
6/10
Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatinib (third-generation
Jun 14, 2026
NEUTRAL
6-K
4/10
Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, including first pediatric
Jun 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | — |
| Point72 Asset Management, L.P. | $383.3K | — |
| MORGAN STANLEY | $11.9K | DOUBLED |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | Yang Dajun | M | $0.00 |
| May 21, 2026 | Zhai Yifan | M | $0.00 |
| May 20, 2026 | Yang Dajun | A | $0.00 |
| May 20, 2026 | Yang Dajun | A | $0.00 |
| May 20, 2026 | Zhai Yifan | A | $0.00 |
3 institutional holders with $395.1K total value (16,560 shares) as of 2026-Q1. Top holders: ROYAL, Point72, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 6 | $0.00 | 0.0% | — |
| 2 | Point72 Asset Management, L.P. | 16,056 | $383.3K | 97.0% | — |
| 3 | MORGAN STANLEY | 498 | $11.9K | 3.0% | DOUBLED +225.5% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 153 | 498 | +225.5% | $11.9K | 2026-Q1 |
| UBS Group AG | DOUBLED | 7,357 | 18,345 | +149.4% | $716.2K | 2025-Q3 |
| NEOS Investment Management LLC | TRIM | 15,495 | 10,385 | -33.0% | $412.2K | 2025-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 956 | 203 | -78.8% | $7.9K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,478 | 7,357 | +196.9% | $289.7K | 2025-Q2 |
3 unique insiders with 7 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | Yang Dajun | Chairman and CEO | EXERCISE | 95,575 | — | — |
| May 21, 2026 | Zhai Yifan | Chief Medical Officer | EXERCISE | 92,746 | — | — |
| May 20, 2026 | Yang Dajun | Chairman and CEO | AWARD | 95,575 | — | — |
| May 20, 2026 | Yang Dajun | Chairman and CEO | AWARD | 298,194 | — | — |
| May 20, 2026 | Zhai Yifan | Chief Medical Officer | AWARD | 214,988 | — | — |
| May 20, 2026 | Zhai Yifan | Chief Medical Officer | AWARD | 103,365 | — | — |
| Apr 20, 2026 | Misra Veet | Chief Financial Officer | AWARD | 18,584 | — | — |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 0 bearish, 1 mixed, 8 neutral. Avg impact: 3.8/10.
BULLISH
6-K
6/10
Ascentage Pharma presented 17 clinical updates at the EHA2026 Congress, including data from its two
Jun 15, 2026
NEUTRAL
6-K
4/10
Ascentage Pharma presented positive clinical data for three key drug candidates at ASCO 2026, includ
Jun 1, 2026
NEUTRAL
6-K
2/10
Ascentage Pharma disclosed that its trustee purchased 50,000 existing shares on-market for HK$1,909,
May 28, 2026
NEUTRAL
6-K
2/10
Ascentage Pharma issued a voluntary announcement that its RSU trustee purchased 100,000 existing sha
May 28, 2026
NEUTRAL
6-K
5/10
Ascentage Pharma filed a 6-K furnishing its third amended and restated memorandum and articles of as
May 22, 2026
NEUTRAL
6-K
3/10
Ascentage Pharma announced it will present 17 clinical advances, including 8 poster presentations, a
May 13, 2026
NEUTRAL
6-K
2/10
Ascentage Pharma announced management participation in three upcoming investor conferences (B. Riley
May 12, 2026
BULLISH
6-K
7/10
Ascentage Pharma announced that six abstracts from clinical studies of its key drug candidates will
Apr 22, 2026
NEUTRAL
6-K
3/10
Ascentage Pharma announced four preclinical studies at AACR 2026, highlighting potential new uses fo
Apr 20, 2026
NEUTRAL
6-K
1/10
Ascentage Pharma Group International announced a change in its principal place of business in Hong K
Apr 1, 2026
MIXED
6-K
7/10
Ascentage Pharma reported its 2025 annual results, showing a 41.5% year-over-year revenue decline to
Mar 26, 2026
MIXED
6/10
Ascentage Pharma presented 17 clinical updates at EHA2026, including eight posters, for olverembatin
Jun 14, 2026
NEUTRAL
4/10
Ascentage Pharma announced that six abstracts from its clinical studies were selected for presentati
May 22, 2026
BULLISH
7/10
Ascentage Pharma announced that six clinical study abstracts for its key drug candidates—Olverembati
Apr 22, 2026
NEUTRAL
3/10
Ascentage Pharma announced it will present four preclinical studies at the AACR 2026 Annual Meeting.
Apr 20, 2026
MIXED
6/10
Ascentage Pharma reported unaudited 2025 financial results showing a 41.5% year-over-year decline in
Mar 25, 2026
NEUTRAL
4/10
Ascentage Pharma announced that four preclinical abstracts from its drug pipeline, including data on
Mar 18, 2026
NEUTRAL
3/10
Ascentage Pharma announced it will release its full year 2025 unaudited financial results on March 2
Mar 11, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 12 analysts: 5 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$47.56 mean target
+179.6% upside
Strong Buy (1.22)
$40.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $17.01 |
| Target Low | $40.00 |
| Target Mean | $47.56 |
| Target Median | $48.00 |
| Target High | $55.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.22) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$-0.58 | $-0.58 | $-0.58 | — | +0.0% | — | $0.1B | — | 1 |
| Next Q 2026-06-30 |
$-0.51 | $-0.51 | $-0.51 | — | +0.0% | — | $0.2B | — | 1 |
| Current FY 2026-12-31 |
$-1.52 | $-2.50 | $-0.43 | 24.0% | +0.0% | 0↑ 5↓ | $0.8B | 47.3% | 5 |
| Next FY 2027-12-31 |
$-1.20 | $-2.28 | $-0.28 | 21.4% | +0.0% | 0↑ 3↓ | $1.5B | 72.5% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.580 | |
| 7d ago | $-0.580 | |
| 30d ago | $-0.580 | |
| 60d ago | $-0.580 | |
| 90d ago | $0.000 | -0.580 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 15, 2026 | BTIG | REITERATE | Buy | Buy |
| Jun 10, 2026 | B. Riley Securities | INITIATE | — | Buy |
| Apr 13, 2026 | BTIG | REITERATE | Buy | Buy |
| Mar 26, 2026 | BTIG | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 6 | 7 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Feb 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% | |
| Jan 1, 2026 | 5 | 7 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 14, 2026
fda
Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 685
May 31, 2026
earnings
Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855
May 31, 2026
routine
Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855
May 31, 2026
routine
Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855
May 22, 2026
fda
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855
May 13, 2026
other
Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855
Apr 22, 2026
fda
Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 68
Apr 20, 2026
fda
Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 68
Mar 25, 2026
earnings
Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, March 25, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NAS
Mar 18, 2026
earnings
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 68
Mar 11, 2026
earnings
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
<p align="justify">ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NAS